A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens

• Published in: npj vaccines Vol. 9; no. 1; pp. 151 - 17
• Main Authors: Kramarska, Eliza, Toumi, Eya, Squeglia, Flavia, Laverde, Diana, Napolitano, Valeria, Frapy, Eric, Autiero, Ida, Sadones, Oceane, Huebner, Johannes, Skurnik, David, Romero-Saavedra, Felipe, Berisio, Rita
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 18.08.2024; Nature Publishing Group UK; Nature Portfolio
• Subjects: Antibiotic resistance; Antibiotics; Antibodies; Antigens; Immunization; Nosocomial infection; Pathogens; Staphylococcus infections
• ISSN: 2059-0105; 2059-0105
• DOI: 10.1038/s41541-024-00940-x

SummaryESKAPE pathogens are responsible for complicated nosocomial infections worldwide and are often resistant to commonly used antibiotics in clinical settings. Among ESKAPE, vancomycin-resistant Enterococcus faecium (VREfm) and methicillin-resistant Staphylococcus aureus (MRSA) are two important Gram-positive pathogens for which non-antibiotic alternatives are urgently needed. We previously showed that the lipoprotein AdcA of E. faecium elicits opsonic and protective antibodies against E. faecium and E. faecalis. Prompted by our observation, reported here, that AdcA also elicits opsonic antibodies against MRSA and other clinically relevant Gram-positive pathogens, we identified the dominant epitope responsible for AdcA cross-reactive activity and designed a hyper-thermostable and multi-presenting antigen, Sc(EH)3. We demonstrate that antibodies raised against Sc(EH)3 mediate opsonic killing of a wide-spectrum of Gram-positive pathogens, including VREfm and MRSA, and confer protection both in passive and active immunisation models. Our data indicate that Sc(EH)3 is a promising antigen for the development of vaccines against different Gram-positive pathogens.